Recruiting
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
NCT06792825
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Masonic Cancer Center Minneapolis, Minnesota, United States